BETRF — BetterLife Pharma Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1464165 ·
Last close
$0.15
Market Cap
$25.64M
52W High
$0.33
52W Low
$0.03
ADV30
89,680
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -1,175,621 | -2,084,763 | 2,046,481 | 973,593 | 9,704,127 |
| Apr 2026 | 0 | — | -561,395 | -609,257 | 242,428 | 28,576 | 6,676,796 |
| Jan 2026 | 0 | — | -437,008 | -380,547 | 219,903 | 12,570 | 6,706,283 |
| Oct 2025 | 0 | — | -389,215 | -409,014 | 291,127 | 7,962 | 6,456,866 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,082,351
Investing CF
—
Financing CF
$3,033,563
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.02
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-122,785,512
Inventory
—
Receivables
$49,540
ST Investments
—
EBIT TTM
$-3,302,556
Pretax Income TTM
$-3,505,919
Interest Exp TTM
$203,363
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | -1,808,600 | -1,495,492 | 219,903 | 6,706,283 | -9,784,058 | -625,455 |
| Jan 2025 | 0 | -4,724,931 | -3,520,288 | 224,963 | 7,587,112 | -10,677,529 | -2,021,752 |
| Jan 2024 | 0 | -3,209,889 | -2,889,032 | 324,746 | 8,020,513 | -10,808,521 | -2,472,410 |
| Jan 2023 | 0 | -9,257,441 | -9,016,201 | 74,727 | 7,608,197 | -10,728,221 | -1,503,512 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-6,742,902
OpCashFlow TTM
—
Assets (Latest)
$7,079,877
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | $25.36M | $0.94 | — |
| BIOE | Bio Essence Corp | $25.29M | $0.47 | — |
| ACET | Adicet Bio, Inc. | $26.03M | $2.78 | — |
| AARD | Aardvark Therapeutics, Inc. | $25.17M | $1.15 | — |
| CLCS | Cell Source, Inc. | $25.14M | $0.37 | — |
News headlines (Yahoo Finance, 1h cache)
BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026
2026-11-17 13:15 · Yahoo
BetterLife Pharma Announces Stock Option Grant
2026-11-17 13:00 · Yahoo
BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha
2026-11-06 13:00 · Yahoo
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
2026-11-05 13:00 · Yahoo
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
2026-10-27 12:00 · Yahoo
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
2026-10-19 12:00 · Yahoo
Canadian Securities Exchange Reports September 2026 Performance Figures
2026-10-16 19:53 · Yahoo
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
2026-10-15 12:00 · Yahoo
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
2026-10-14 12:00 · Yahoo
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
2026-10-09 19:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.